TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status

<p>Abstract</p> <p>Background</p> <p>Although there have been many studies on the p73 gene, some of its functions still remain unclear. There is little research on the relationship between p73 gene transcription and its protein expression and the response to certain dru...

Full description

Bibliographic Details
Main Authors: Cavia-Saiz Mónica, García-Girón Carlos, Muñiz Pilar, Herreros-Villanueva Marta, del Corral María
Format: Article
Language:English
Published: BMC 2010-02-01
Series:Journal of Translational Medicine
Online Access:http://www.translational-medicine.com/content/8/1/15
_version_ 1818199346543329280
author Cavia-Saiz Mónica
García-Girón Carlos
Muñiz Pilar
Herreros-Villanueva Marta
del Corral María
author_facet Cavia-Saiz Mónica
García-Girón Carlos
Muñiz Pilar
Herreros-Villanueva Marta
del Corral María
author_sort Cavia-Saiz Mónica
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>Although there have been many studies on the p73 gene, some of its functions still remain unclear. There is little research on the relationship between p73 gene transcription and its protein expression and the response to certain drugs such as oxaliplatin and cetuximab, which are drugs currently used in colorectal cancer.</p> <p>The purpose of this study was to evaluate the impact of TAp73 expression on oxaliplatin and cetuximab-based chemotherapy in colorectal cancer cell lines with different K-Ras and B-Raf mutational status.</p> <p>Methods</p> <p>TAp73 was analyzed in three colorectal tumor cell lines HT-29, SW-480 and Caco-2. mRNA TAp73 was determined using Real time PCR; TAp73 protein by immunoblotting and cell viability was analyzed by the MTT method.</p> <p>Results</p> <p>We found that mRNA and TAp73 protein were decreased in cells treated with oxaliplatin (in monotherapy or combined with cetuximab) when B-Raf is mutated. This was statistically significant and was also associated with higher cell viability after the treatment.</p> <p>Conclusions</p> <p>Here, for the first time we report, that there is a signaling loop between B-Raf activation and p73 function.</p> <p>Low expression of TAp73 in colorectal cancer cell lines with mutated B-Raf may be involved in the lack of response to oxaliplatin in monotherapy or combined with cetuximab.</p>
first_indexed 2024-12-12T02:20:18Z
format Article
id doaj.art-6d0662f40623476aa46f2a1f10b5dbf8
institution Directory Open Access Journal
issn 1479-5876
language English
last_indexed 2024-12-12T02:20:18Z
publishDate 2010-02-01
publisher BMC
record_format Article
series Journal of Translational Medicine
spelling doaj.art-6d0662f40623476aa46f2a1f10b5dbf82022-12-22T00:41:42ZengBMCJournal of Translational Medicine1479-58762010-02-01811510.1186/1479-5876-8-15TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational statusCavia-Saiz MónicaGarcía-Girón CarlosMuñiz PilarHerreros-Villanueva Martadel Corral María<p>Abstract</p> <p>Background</p> <p>Although there have been many studies on the p73 gene, some of its functions still remain unclear. There is little research on the relationship between p73 gene transcription and its protein expression and the response to certain drugs such as oxaliplatin and cetuximab, which are drugs currently used in colorectal cancer.</p> <p>The purpose of this study was to evaluate the impact of TAp73 expression on oxaliplatin and cetuximab-based chemotherapy in colorectal cancer cell lines with different K-Ras and B-Raf mutational status.</p> <p>Methods</p> <p>TAp73 was analyzed in three colorectal tumor cell lines HT-29, SW-480 and Caco-2. mRNA TAp73 was determined using Real time PCR; TAp73 protein by immunoblotting and cell viability was analyzed by the MTT method.</p> <p>Results</p> <p>We found that mRNA and TAp73 protein were decreased in cells treated with oxaliplatin (in monotherapy or combined with cetuximab) when B-Raf is mutated. This was statistically significant and was also associated with higher cell viability after the treatment.</p> <p>Conclusions</p> <p>Here, for the first time we report, that there is a signaling loop between B-Raf activation and p73 function.</p> <p>Low expression of TAp73 in colorectal cancer cell lines with mutated B-Raf may be involved in the lack of response to oxaliplatin in monotherapy or combined with cetuximab.</p>http://www.translational-medicine.com/content/8/1/15
spellingShingle Cavia-Saiz Mónica
García-Girón Carlos
Muñiz Pilar
Herreros-Villanueva Marta
del Corral María
TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status
Journal of Translational Medicine
title TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status
title_full TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status
title_fullStr TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status
title_full_unstemmed TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status
title_short TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status
title_sort tap73 is one of the genes responsible for the lack of response to chemotherapy depending on b raf mutational status
url http://www.translational-medicine.com/content/8/1/15
work_keys_str_mv AT caviasaizmonica tap73isoneofthegenesresponsibleforthelackofresponsetochemotherapydependingonbrafmutationalstatus
AT garciagironcarlos tap73isoneofthegenesresponsibleforthelackofresponsetochemotherapydependingonbrafmutationalstatus
AT munizpilar tap73isoneofthegenesresponsibleforthelackofresponsetochemotherapydependingonbrafmutationalstatus
AT herrerosvillanuevamarta tap73isoneofthegenesresponsibleforthelackofresponsetochemotherapydependingonbrafmutationalstatus
AT delcorralmaria tap73isoneofthegenesresponsibleforthelackofresponsetochemotherapydependingonbrafmutationalstatus